Table 2 Characteristics of patients in the COPD subgroups

Sex

(male/female)

42/9

91/21

65/13

0.933

Age

(years)

71.98 ± 1.13

71.93 ± 0.77

70.62 ± 0.92

0.426

Hypertension

( +)/(–)

28/23

68/44

40/38

0.422

Diabetes mellitus

( +)/(–)

10/41

23/89

16/62

0.989

Smoking

( +)/(–)

45/6

93/19

67/11

0.667

Intervention period

(days)

25.88 ± 1.81

22.52 ± 1.22

23.26 ± 1.46

0.348

VC

(mL)

3184.71 ± 102.60

3162.32 ± 69.23

3488.46 ± 82.96

0.0079(ICS/LABA vs. LAMA/LABA)

%VC

(%)

104.53 ± 2.63

105.70 ± 1.77

112.32 ± 2.12

0.0462(ICS/LABA vs. LAMA/LABA)

FEV1.0

(mL)

1975.29 ± 69.05

1963.84 ± 46.59

2118.85 ± 55.83

0.0845

%FEV1.0

(%)

95.84 ± 3.10

93.24 ± 2.07

94.86 ± 2.48

0.757

FEV1.0%

(%)

64.01 ± 1.10

62.25 ± 0.74

61.13 ± 0.89

0.125

%DLco

(%)

97.74 ± 4.18

105.43 ± 2.74

113.23 ± 3.36

0.02(LAMA vs. LAMA/LABA)

GOLD stage

 I

41

80

63

0.816

 II

10

30

14

 III

0

2

1

Pathology

Ad

24

64

50

0.094

Sq

14

30

22

Other

13

18

6

Surgical procedure; Lobectomies

 LUL

12

18

18

0.708

 LLL

7

13

14

 RUL

16

38

23

 RLL

12

19

16

 RML

0

5

4

Surgical procedure; Reduction surgery and enlargement surgery

 Segmentectomy

2

19

1

0.001

 Extended Surgery

2

0

2